Titre :
  • Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.
Auteur : Piccart-Gebhart, Martine ; Bertelsen, K ; Stuart, G ; Cassidy, J ; Mangioni, C ; Simonsen, E ; James, K ; Kaye, S ; Vergote, Ignace ; Blom, R ; Grimshaw, R ; Atkinson, R ; Swenerton, K ; Trope, C ; Nardi, M ; Kaern, J ; Tumolo, Salvatore ; Timmers, P ; Roy, J A ; Lhoas, F ; Lidvall, B ; Bacon, M ; Birt, A ; Andersen, J E ; Zee, B ; Paul, J ; Pecorelli, Sërgio ; Baron, Benoît ; Mcguire, William Patrick
Informations sur la publication : International journal of gynecological cancer, 13 Suppl 2, (page 144-148)
Statut de publication : Publié, 2003
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Canada
Cisplatin -- administration & dosage
Cyclophosphamide -- administration & dosage
Europe
Female
Follow-Up Studies
Humans
Longitudinal Studies
Neoplasm Staging
Ovarian Neoplasms -- drug therapy
Ovarian Neoplasms -- mortality
Ovarian Neoplasms -- pathology
Paclitaxel -- administration & dosage
Randomized Controlled Trials as Topic
Survival Analysis
Note : Clinical Trial
Journal Article
Randomized Controlled Trial
Langue :
  • Anglais
Identificateurs : urn:issn:1048-891X 
info:pii/13357
info:pmid/14656271